1-5 of 5
German Austrian AML Study Group (AMLSG)
Close
Sort by
Journal Articles

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Clinical Trials & Observations
Bob Löwenberg, Joachim Beck, Carlos Graux, Wim van Putten, Harry C. Schouten, Leo F. Verdonck, Augustin Ferrant, Pieter Sonneveld, Mojca Jongen-Lavrencic, Marie von Lilienfeld-Toal, Bart J. Biemond, Edo Vellenga, Dimitri Breems, Hilde de Muijnck, Ron Schaafsma, Gregor Verhoef, Hartmut Döhner, Alois Gratwohl, Thomas Pabst, Gert J. Ossenkoppele, Johan Maertens, for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German Austrian AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research Collaborative Group (SAKK)
Journal: Blood
Blood (2010) 115 (13): 2586–2591.
https://doi.org/10.1182/blood-2009-10-246470
Published: 2010
Journal Articles

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

Clinical Trials & Observations
Sabine Kayser, Richard F. Schlenk, Martina Correa Londono, Frank Breitenbuecher, Kerstin Wittke, Juan Du, Silja Groner, Daniela Späth, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Thomas Fischer, Konstanze Döhner, for the German-Austrian AML Study Group (AMLSG)
Journal: Blood
Blood (2009) 114 (12): 2386–2392.
https://doi.org/10.1182/blood-2009-03-209999
Published: 2009
Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.

Richard F. Schlenk, MD, Konstanze Doehner, MD, Martina Kerz, Frank Hartmann, MD, Francesco del Valle, MD, Axel Glasmacher, MD, Hans Pralle, MD, Katharina Goetze, MD, Elisabeth Koller, MD, Guenther Gastl, MD, Hans G. Mergenthaler, MD, Hans Salwender, MD, Heinz Kirchen, MD, Detlef Haase, MD, Stephan Kremers, MD, Christoph Nerl, MD, Matthias Theobald, MD, Axel C. Matzdorff, MD, Arnold Ganser, MD, Hartmut Doehner, MD, for the German-Austrian, AML Study Group (AMLSG)
Journal: Blood
Blood (2005) 106 (11): 1849.
https://doi.org/10.1182/blood.V106.11.1849.1849
Published: 2005
Journal Articles

Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.

Richard F. Schlenk, MD, Andrea Corbacioglu, PhD, Stefan Fröhling, MD, Juan Du, MD, Daniela Späth, Irina Schäfer, Jürgen Krauter, MD, Arnold Ganser, MD, Hartmut Döhner, MD, Konstanze Döhner, MD, for the German-Austrian, AML Study Group (AMLSG)
Journal: Blood
Blood (2005) 106 (11): 2352.
https://doi.org/10.1182/blood.V106.11.2352.2352
Published: 2005
Journal Articles

Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3 -ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype.

Richard F. Schlenk, MD, Jürgen Krauter, MD, Stefan Fröhling, MD, Daniela Späth, Irina Schäfer, MD, Stefan Hein, Hartmut Döhner, MD, Arnold Ganser, MD, Konstanze Döhner, MD, for the German-Austrian AML Study Group (AMLSG)
Journal: Blood
Blood (2005) 106 (11): 2353.
https://doi.org/10.1182/blood.V106.11.2353.2353
Published: 2005